Most commercial scorecards are built from activity: calls made, emails sent, reach and frequency against plan, events held. They are easy to count and they matter, because a plan that is not executed cannot work. What they cannot tell a leadership team is whether any of that activity made a difference to the people it was meant for.
Commercial excellence looks different when it is measured from the customer's side. The question changes from "did we do what we planned?" to "what changed for the physician, the patient and the health system, and did our teams help?"
Outcome indicators a commercial team can own
Commercial teams do not make clinical decisions, and their indicators should not pretend otherwise. They can, however, measure whether they made it easier for physicians and patients to act. A few examples that brand, field and operations teams can read from their own data:
- For physicians and care teams: how long a clinical question takes to reach an answer through the channel the physician prefers; contacts per physician, alongside whether physicians rate them as relevant; and how often field and digital teams contact the same physician without coordinating.
- For patients and caregivers: time from prescription to first dose at supported accounts; the share of starts that stall in prior authorization or at the specialty pharmacy; and whether support programs are reviewed on what changes for patients rather than on enrollment counts.
- For payers and health systems: whether account plans reflect how each payer, IDN and specialty pharmacy actually decides, and how quickly access changes reach the physicians and patients they affect.
Putting them to work
- Pick a few, not twenty Three to five outcome indicators per brand, chosen with the field and patient program teams, beat a long list nobody reviews.
- Pair each with the activity that should move it If time to first dose is the indicator, the related activities are hub follow-up, account support and access updates, and the review looks at both together.
- Bring them into the operating review Outcome indicators that sit in a separate deck are read once. Placed next to the activity metrics, they change where the next quarter's effort goes.
- Keep incentives honest Indicators that reward relevance and coordination are healthy. Anything that could read as paying for prescribing is not, and compliance should review the design before launch.
Limits worth stating
Outcome indicators move more slowly and are shaped by many things a commercial team does not control, from payer policy to clinical practice. They are a guide to where effort helps, not a scorecard for individuals. Data on patients must stay de-identified and within consent rules, which sometimes limits what can be measured at account level.
We set out these indicators stage by stage for physicians and patients, and build them into the field, engagement and measurement work of commercial and customer excellence.